Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (MOVE) pioneers wearable health technology that transforms personal wellness through medical-grade data collection. This page aggregates official announcements, financial updates, and strategic developments from the creator of the Evie Ring—a women-focused wearable tracking metabolic health indicators like glucose trends and heart rate variability.
Investors and industry observers will find curated press releases covering product launches, FDA clearances, and enterprise partnerships. Key updates include earnings reports, clinical validation milestones, and expansions into chronic disease management markets. All content is vetted for accuracy and relevance to health tech innovation.
Bookmark this page for streamlined access to Movano's evolving role in bridging consumer wearables with clinical insights. Check regularly for developments in sensor technology advancements and new applications of its AI-driven health analytics platform.
Movano Inc. (Nasdaq: MOVE), a health technology company, announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15 to February 17, 2022. CEO John Mastrototaro will present the company’s debut device, the Movano Ring, which was showcased at CES 2022. Founded in 2018, Movano focuses on creating personalized health devices that provide vital health data, including glucose and blood pressure. For further details, visit movano.com.
Movano Inc. (Nasdaq: MOVE) announced the award of three new U.S. patents, bringing its total to six. The patents focus on non-invasive sensor technology that combines Radio Frequency (RF) and mmWave capabilities into a single Integrated Circuit (IC) for future wearable devices. With over 40 pending applications, the company aims to provide health metrics like glucose and blood pressure. CEO John Mastrototaro emphasized that these innovations will enhance data accuracy and differentiate Movano’s products in the market.
Movano Inc. (Nasdaq: MOVE), a health technology company, will participate in the 24th Annual Needham Virtual Growth Conference on January 12, 2022. CEO John Mastrototaro, with over 30 years in the medical device sector, will present the company's innovative Movano Ring, recently revealed at CES 2022. Founded in 2018, Movano focuses on creating user-friendly health devices that provide essential health insights like glucose and blood pressure data to enhance individual well-being.
Movano Inc (NASDAQ:MOVE) announced the completion of an Institutional Review Board (IRB)-approved blood pressure study involving 110 participants conducted in late 2021. The study utilized Movano's wearable prototypes and a hospital-grade monitor for data comparison. This research is vital for advancing Movano's algorithms for smart medical devices. CEO John Mastrototaro highlighted that the study results will inform future product development, including the goal of obtaining FDA clearances for their devices. A second glucose study is also planned for Q1 2022.
Movano Inc. (Nasdaq: MOVE) is set to showcase its first device, the Movano Ring, at CES 2022. This innovative health-tech ring is designed specifically for women, providing vital health metrics and personalized feedback. It measures several health indicators, including heart rate and sleep, helping users connect lifestyle habits to health outcomes. Movano aims to gain FDA clearances for additional features like glucose monitoring. The Movano Ring is expected to be one of the most affordable health devices available, with a beta release planned for the second half of 2022.
Movano Inc. (NASDAQ:MOVE) reported its financial results for Q3 2021, highlighting a net loss of $5.2 million, or $0.16 per share, an improvement from a $5.7 million loss in Q3 2020. The company remains in the development stage, generating no revenue. Movano has initiated clinical testing for its first wearable device prototype and completed the tapeout of its single-chip solution, a significant development milestone. With $39.3 million in cash as of September 30, 2021, Movano is preparing to showcase its technology at CES 2022 and explore strategic partnerships.
Movano Inc. (NASDAQ: MOVE) announced its participation in the Bernstein CGM Disruptors Conference on November 19, 2021. CEO John Mastrototaro will engage in a virtual fireside chat discussing the future of continuous glucose monitoring systems and connected health solutions aimed at preventing chronic diseases. Movano, established in 2018, develops personalized health devices offering crucial data such as glucose and blood pressure, enhancing users' ability to manage their health effectively.
Movano Inc (NASDAQ:MOVE) will report its third quarter 2021 financial and operational results on November 11, 2021. The company specializes in health technology, creating devices aimed at optimizing individual health and managing chronic diseases. A conference call will take place at 2:00 p.m. PDT for a business update. Movano's devices aim to provide crucial health metrics, such as glucose and blood pressure data, tailored to user preferences. The press release highlights the company’s forward-looking statements, cautioning investors about inherent risks and uncertainties.
Movano Inc. (NASDAQ:MOVE) reported its second quarter 2021 financial results, reflecting a net loss of $4.7 million, or $0.15 per share, improved from a $4.9 million loss in Q2 2020. The company continues to advance its health technology, receiving IRB approval for clinical studies and aiming to launch a new wearable device prototype by late Q3 or early Q4 2021. Movano also holds $42.7 million in cash and investments as of June 30, 2021, a significant increase from $5.7 million at year-end 2020, signaling robust financial health for ongoing R&D.
Movano Inc. (NASDAQ:MOVE) will report its Q2 2021 financial results on August 12, 2021.
Management will host a conference call at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss these results and provide a business update. The live webcast can be accessed on the investors section of Movano's website. Movano focuses on creating health technology devices aimed at optimizing health and managing chronic diseases.
